A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene (HEARCONNEX)
An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability
This study intends to assess safety, tolerability, and efficacy of SENS-601, injected with SPHYNX administration system, in children between 6 months and 6 years of age, with hearing loss related to pathogenic variation(s) of GJB2 gene.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Lionel HOVSEPIAN
- 電話番号:+33(0)686 831 180
- メール:contact@sensorion-pharma.com
研究場所
-
-
-
Paris、フランス、75015
- 募集
- Hopital Necker Enfants Malades
-
コンタクト:
- Centre de Recherche en Audiologie pédiatrique
- 電話番号:+33(0)187 892 916
- メール:rdv.crea.nck@aphp.fr
-
主任研究者:
- Natalie LOUNDON
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Males or females aged ≥6 months to ≤6 years.
- Congenital bilateral severe sensorineural hearing loss.
- Biallelic GJB2 variation(s).
- Documented normal cochlea and internal auditory canals.
Exclusion Criteria:
- History of chronic, acute, or major disease.
- Have been dosed in a previous gene therapy clinical study.
- Other causes or risk of hearing loss, including developmental disorders, unilateral hearing loss, chronic conductive hearing loss, malformation syndrome, syndromic hearing loss or any other cause that would impact negatively the response of hair cell function, history of therapy known as ototoxic for an extended period, or documented other causes of congenital bilateral hearing loss linked to mutations in genes other than GJB2.
- Prior or current cochlear implant in the ear to be treated with SENS-601.
- Contraindication to corticosteroid therapy and/or immunosuppressive or immunomodulatory therapy or to the planned surgery, to anesthesia or increased anesthesiologic risk.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dose escalation - Dose Level 1
Intracochlear administration of Dose level 1 of SENS-601 in one ear, with the SPHYNX injection system |
Administration of SENS-601 with the SPHYNX injection system |
|
実験的:Dose escalation - Dose Level 2
Intracochlear administration of Dose level 2 of SENS-601 in one ear, with the SPHYNX injection system |
Administration of SENS-601 with the SPHYNX injection system |
|
実験的:Dose expansion group
Intracochlear administration of SENS-601 in both ears, with the SPHYNX injection system, at the dose recommended following the Dose escalation phase |
Administration of SENS-601 with the SPHYNX injection system |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and tolerability of SENS-601 and SPHYNX administration system
時間枠:5 years
|
The incidence and severity of Treatment-Emergent Adverse Events (TEAEs). The incidence and severity of Adverse Device Events, Serious Adverse Device Effects, and Device Deficiencies |
5 years
|
|
Efficacy of SENS-601 assessed by ABR
時間枠:5 years
|
Change from baseline of hearing threshold measured by auditory brainstem response (ABR) |
5 years
|
|
Efficacy of SENS-601 assessed by PTA
時間枠:5 years
|
Change from baseline of hearing threshold measured by pure-tone audiometry (PTA) |
5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
SPHYNX Injection system performance
時間枠:Day 1
|
Incidence of successful administrations, based on user questionnaires |
Day 1
|
|
SPHYNX Injection System clinical benefit
時間枠:Day 1
|
Incidence of failed surgeries due to SPHYNX injection system, based on "SENS-601 injection form" user questionnaires |
Day 1
|
|
Usability of the administration system
時間枠:Day 1
|
Evaluation of the degree to which users were able to effectively, efficiently, and safely use the devices in their specific environments, based on "Usability assessment" user questionnaire |
Day 1
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- SENS-601-101
- 2026-525698-38-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。